CVKD

← Markets

CVKDCadrenal Therapeutics, Inc.

Discussion

Nothing said here yet.

to join the conversation.

—

Thu, Aug 13
3:15 PMYahooCadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering Process
Mon, Aug 3
11:15 AMYahooCVKD: Positive CAD-1005 Data Accelerates Transition Toward Business Development Strategy
7:30 AMYahooCadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 Discontinuation
Tue, Jul 21
7:00 AMYahooCadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation
Mon, Jul 13
8:00 AMYahooCadrenal Therapeutics’ Late-Breaking Phase 2 Data Demonstrate Greater Than 25% Reduction in Thrombotic Events in HIT for First-in-Class 12-LOX Inhibitor CAD-1005 at ISTH 2026 Congress
Tue, Jun 30
7:00 PMYahooCadrenal Therapeutics Announces up to $8.8 Million Private Placement Priced At-The-Market Under Nasdaq Rules
Wed, Jun 24
7:00 AMYahooCadrenal Therapeutics Announces Selection of CAD-1005 Phase 2 Study for Late-Breaking Oral Presentation at ISTH 2026 Congress
Thu, Jun 18
8:00 AMYahooCadrenal Therapeutics to File for FDA Rare Pediatric Disease Designation for Tecarfarin in Kawasaki Disease
Mon, Jun 15
7:30 AMYahooCadrenal Therapeutics Advances Multi-Indication Strategy for CAD-1005; Launches Phase 2a Acute Kidney Injury (CSA-AKI) Clinical Plan to Accelerate Pharma Partnering at Upcoming BIO 2026
Wed, Jun 3
8:00 AMYahooCadrenal Therapeutics to Showcase Phase 3-Ready CAD-1005 and Novel 12-LOX Platform at BIO International Convention 2026 Partnering Event
Tue, May 19
3:30 PMYahooCadrenal Therapeutics to Participate in the Lytham Partners Spring 2026 Investor Conference on May 28, 2026
Fri, May 8
7:15 AMYahooCVKD: Designing Phase 3 Trial for CAD-1005 in HIT